Also Included In: Public Health; Regulatory Affairs / Drug Approvals
Article Date: 08 Dec 2011 - 0:00 PST
email to a friend 
printer friendly 
opinions 
In this week's PLoS Medicine, Paul Newton of Mahosot Hospital, Vientiane, Lao PDR and the University of Oxford, UK and colleagues argue that public health issues, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines. They say that the World Health Organization (WHO) should take a more prominent role.
The authors advocate that an international treaty on medicine quality, under the auspices of the WHO, could play a key role in the struggle against counterfeit and substandard medicines.
The authors comment that: "Counterfeit medicines should be defined in terms of harm to health, with punishments appropriate for the injury or killing of patients.
Moreover, it is imperative that public health institutions, ministries, and lawyers, and not primarily IP specialists or industrial and trade bodies, take the strategic lead in countering poor quality medicines."
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.Visit our pharma industry / biotech industry section for the latest news on this subject. Funding: Wellcome Trust (UK) for PNN & NJW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, except for the involvement of Chris Bird as an author.
Competing Interests: PN and NJW have scientific collaborations with the Enforcement Working Group of IMPACT, and NJW is co-chair of the WHO malaria treatment guidelines committee but none of the authors have shares in pharmaceutical companies or works as a part of IMPACT. NJW is a member of the PLoS Medicine Editorial Board. The Wellcome Trust had no role in the writing or decision to submit this viewpoint for publication, except for the involvement of CB as an author. BS is co-founder of MPedigree, which is a non-profit based in Ghana that advocates for the development of strategies to fight counterfeiting. All other authors have declared that no competing interests exist.
Citation: Newton PN, Amin AA, Bird C, Passmore P, Dukes G, et al. (2011) The Primacy of Public Health Considerations in Defining Poor Quality Medicines. PLoS Med 8(12): e1001139. doi:10.1371/journal.pmed.1001139
Public Library of Science Please use one of the following formats to cite this article in your essay, paper or report:
MLA
8 Dec. 2011.
Please note: If no author information is provided, the source is cited instead.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
